Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
NXC-201
product2 mentionslast seen Sep 30, 2026
Sterically-optimized BCMA-targeted CAR-T cell therapy for relapsed/refractory AL Amyloidosis.
Relationships 8
- NXC-201applies torelapsed/refractory AL Amyloidosis treatment99% confidence2 sources
- Immix Biopharma, Inc.developsNXC-20199% confidence2 sources
- U.S. Food and Drug AdministrationapprovesNXC-20199% confidence2 sources
- European Medicines AgencyapprovesNXC-20199% confidence2 sources
- NXC-201depends onchimeric antigen receptor T-cell therapy96% confidence1 source
- NXC-201conforms toOrphan Drug designation90% confidence1 source
- NXC-201conforms toBreakthrough Therapy Designation90% confidence1 source
- NXC-201conforms toRegenerative Medicine Advanced Therapy90% confidence1 source
Relationship
Immix Biopharma, Inc.developsNXC-201
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 30, 2026Immix Biopharma, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201
- filingSEC EDGARSep 29, 2026Immix Biopharma, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201